



KILPEST INDIA LIMITED

REGD. OFFICE & FACTORY :

7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 INDIA

Tel : 91-755 2586536, 2586537

E-mail : kilpest@bsnl.in
info@kilpest.com

Visit us at : www.kilpest.com

CIN : L24211MP1972PLC001131

November 12, 2022

The Relationship Manager,
Department of Corporate Relations
Bombay Stock Exchange Ltd (BSE),
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001

Dear Sir/Madam,

Please find the enclosed herewith Investor's Presentation / Company Update of Agrochemicals and Diagnostic Kits (Health Care) for your information and necessary action.

Thanking you,
Yours faithfully,
For KILPEST INDIA LTD,



Nikhil Kuber Dubey
Whole Time Director
DIN: 00538049

Encl: a/a



3B BlackBio Biotech India Ltd

An ISO 13485:2016 Certified Company




Farmer's Trusted Agro-Input Partner for 50 Years



3B BlackBio Biotech India Ltd

An ISO 13485:2016 Certified Company



Reliable and Affordable Healthcare Diagnostic Solutions

INVESTOR PRESENTATION

NOVEMBER, 2022



Safe Harbour

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.



Kilpest India Ltd.



A milestone year has arrived for Kilpest, 2022. The year in which we celebrate our “Golden Jubilee”.

Kilpest, started with a humble beginning back in 1972. With the introduction of its subsidiary **3B BlackBio Biotech India Limited** in 2011 which is also now over a decade old, we continue to strive to create repeatable successes in the route to becoming a world-class solution provider in healthcare and agrochemical sector. Thanks to the knowledge gained by five decades of experience not only on the national market but also in the international market, supplying agrochemicals & healthcare solutions to the market with the final objective of providing reliable and affordable healthcare solutions to one and all..

Those of you who already know us, are aware that we have stood the tests of time and delivered the best solutions possible to our customers over five memorable decades. On this road, we are one big team. To all our employees, customers, stakeholders and associates – we thank you for your continued trust on us. Throughout its 50-year history **KILPEST** has risen to the occasion again and again with hard work, dedication and cooperation with partners near and far. We look forward to next 50 Years with greater satisfaction to all our stakeholders.

50 years together, thank you...




FINANCIAL PERFORMANCE AND KEY HIGHLIGHTS




Performance Highlights – Q2 2022-23




(CONSOLIDATED)



(CONSOLIDATED)



(CONSOLIDATED)



(CONSOLIDATED)

Rs. In Lakhs

■ Q2 2021-22

■ Q2 2022-23

KILPEST (Consolidated)	Q2 FY22	Q2 FY23
Net Sales	1522.01	1731.11
Profit Before tax	769.79	1083.32
Profit After tax	587.76	831.25
Paid-Up Equity Share Capital	750.81	750.81
Reserves	12455.98	14553.31
Earnings Per Share (Rs.)	7.83	11.07

KILPEST (Standalone)	Q2 FY22	Q2 FY23
Net Sales	440.81	392.87
Profit Before Tax	790.08*	229.80
Profit After Tax	762.87	219.01
Paid-Up Equity share capital	750.81	750.81
Reserves	1515.18	1643.79
Earnings Per Share (Rs.)	10.16	2.92

*Includes Dividend Income

WE ARE PROUD TO BE A PART OF

Forbes Asia

BEST UNDER A
BILLION

2021



3B BlackBio Biotech India Ltd

An ISO 14001:2015 Certified Company



Key Highlights - Agrochemicals

Impact of COVID-19

Company continues to focus on Government business, Public Health/Warehousing sector and Exports. As due to COVID-19, Private agriculture market is uncertain, and management doesn't want to increase financial exposure due to uncertainty.

Main Thrust Area of R&D

- Development of novel formulations for agriculture and public health which are less harmful and cost effective.
- Performance monitoring of existing products/process.
- Improvement in existing products/process with a customer driven approach.

Future Outlook of Agro-chemical Division

Agro-chemical division shall continue with focus on Government business through GeM/Tenders, Public Health, Ware Housing and Exports. The business now with low debt is cash flow positive.

The sales for the agro-chemical division was affected in the Q2 due to heavy monsoon. In the parts where the company is placed and the adjoining areas had recorded double rainfall during this monsoon as compared to the last year. However, the benefits of this excess monsoon can be reaped in the next few months during the Rabi Season.



Kilpest Existing Products

Chemicals		Biologicals	
	No. of Products		No. of Products
• Insecticides	70	• Bio pesticide	07
• Antibacterials	01	• Bio fungicide	01
• Fungicides	15	• Bio fertilizers	05
• Herbicides	11	• Bio nematicides	01
• Public Health	11	• Public Health	02
• Microfertilizers	02	• Health & Hygiene	06
• Chelated Zinc	01	• Repellents	03
• Plant Growth Regulators	02		

Company to increase its focus on brand building on Micro fertilizers / Bio fertilizers and Public Health Products.



Since 1972

Kilpest India Limited,
India's most trusted agro-chemical brand proudly brings




3B BlackBio Biotech India Ltd

An ISO 13485:2016 Certified Company


***First licensed Molecular Diagnostics (IVD)
manufacturing facility
in India under Medical Device Rule 2017***

From the house of
KILPEST INDIA LTD.



Introduction – 3B BlackBio Biotech India Limited

- ❑ Incorporated in the year 2011, “**3B BlackBio Biotech India Limited**”, a subsidiary of **Kilpest India Limited**, is engaged in **Design, Development, Manufacturing and Commercialization of Rapid tests, qPCR tests & NGS based Molecular Diagnostic Kits** for reliable testing on patient samples.
- ❑ We are **ISO 13485:2016 certified, GMP Compliant Biotech R&D Organization** licensed by **CDSCO**, Govt. of India, New Delhi
- ❑ “**TRUPCR®**” is our **registered brand name** for Real-Time PCR based molecular diagnostic kits & “**TRUNGS®**” is our **registered brand name** for NGS based molecular testing kits. “**TRURAPID®**” is our registered brand name for Lateral Flow assays.
- ❑ With over a **decade of experience in R&D**, we have developed **more than 100 tests for molecular testing** and many more are in the pipeline.
- ❑ Proud recipient of the prestigious “**National MSME Award – 2018**” by the **Honourable President of India, Shri Ram Nath Kovind** for our “**TRUPCR® BCR ABL1 Quantitative Kit**”.
- ❑ Honored with “**Outstanding Achievement Award**” in 2022 for the **Second Time** after 2017 for outstanding achievement in Research & Development by “**Federation of Madhya Pradesh Chambers of Commerce**”.
- ❑ **1st company in India** to get the **USFDA approval** for our “**TRUPCR® SARS-CoV-2 RT qPCR Kit**” which has been **EUA approved by USFDA** for testing on **saliva specimens** as well.
- ❑ Received **ISO 13485:2016** accreditation from **BSI, UK**
- ❑ **Largest suppliers of COVID-19 RT PCR Tests** in India to have supplied **over 15 Million tests to more than 400 labs** across 80 cities of India.




TRUPCR® from 3B BlackBio Biotech (I) Ltd.



Our Vision:

To offer reliable, affordable and effective healthcare solutions to all by recognizing the great potential of biotechnology to effectively diagnose rare, chronic and severe illnesses.



Our Mission:

To design and develop molecular diagnostics products of superior quality and value that continuously improves the patient's life. To become a global organization and to be recognized through quality; innovation and competence.

TRUPCR® Growth Story



Commercialization of Reagents & Enzymes

R&D in Molecular Diagnostics

2011-13

Oncology Tests for BCR-ABL1 QT, JAK-2, PML-RARA Launched

NOVARTIS included TRUPCR® BCR-ABL1 Kit in the Global Clinical Trial of its magic bullet "Glivec-400"

2 National Diagnostic Labs started using TRUPCR® Kits

2015

Received Outstanding Achievement Award by FMPCCI

TRUPCR® Kits accepted in Leading Regional Diagnostics Lab in North and East India

Coagulation Panel, Dengue, Chikungunya, HSV1/2 PCR Kits Launched

2017

Breakthrough with bulk order of TRUPCR® H1N1 Detection Kit

Launch of Solid Tumor Markers (EGFR, KRAS, NRAS, BRAF) & Drug Resistance (Carbapenem, MRSA)

2019

Launch of UTI ID & UTI AST Panels

Received "Award of Excellence" as a Leading IVD Company of the Year

Launch of Rapid Antigen Vertical

Launch of UK Subsidiary

2021



2014

MTB, HPV, HPV-HR, HLA-B27 PCR Kits Launched

2016

TRUPCR® Kits are now accepted by renowned Cancer Institutes in India & Prominent Indian National Diagnostic Labs

H1N1, HCV-GT, MTB-MDR, CMV QT PCR Kits Launched

2018

Honoured with National MSME Award – 2018 by President of India

Introduction of Oncology Panels in Indian IVD Industry by an Indian Manufacturer (AML, ALL, MPN, Leukaemia Fusion)

2020 – COVID-19 YEAR

ICMR Approved COVID RT-PCR Kit Launched. Received USFDA-EUA Approval

Launched Acute Leukemia Panel, Pediatric Leukemia Panel



2022

Received ISO 13485:2016 Accreditation from BSI, UK

Awarded with the "Outstanding Achievement Award – 2021" for outstanding achievement in R&D by FMPCCI, Madhya Pradesh




Life Sciences Company

A Leading Molecular Diagnostics Company


2013:
Headcount: 5
Revenue: ₹ 9.04 Million
Products: 3


2018:
Headcount: 20
Revenue: ₹ 76.50 Million
Products: 50

2022:
Headcount: 35
Revenue: ₹ 668.28 Million
Products: 100+




Growth Canvas








Financial Highlights – Q2 22-23



Q2 FY 2021-22
Q2 FY 2022-23



Rs. In Lakhs.




Business Outlook

Our Q2 Sales has been INR 1423.23 Lakhs* (This includes COVID Sales of INR 93.08 Lakhs). Sales from TRUPCR Europe Limited, Manchester for INR 61.04 Lakhs have also been consolidated in the Q2 sales figures. The sales for Q2 for UK subsidiary is reduced as the team was more focused on getting the ISO accreditation during this quarter.

In Q2 2022-23, the Export Sale for molecular diagnostic kits was INR 278.89 Lakhs. Our products have been well-accepted in more than 25 countries across the world which includes United Kingdom, United States of America, Germany, Romania, Italy, Switzerland, Poland, Austria, Netherlands, France, Singapore, Malaysia, Georgia, United Arab Emirates, Iraq, Kenya, Bolivia, Peru among others.

With COVID, the number of labs have increased and we are trying to increase our footprints for NON-COVID products in these labs. Also, we are launching new products out of R&D. We expect with the addition of new products and new customers, we will continue to grow and expand in this financial year also.



Our Strategic Priorities



Market Penetration:

We plan to increase our sales with existing customers / channel partners by adding more products to their current portfolio.




Portfolio Expansion:

With our extensive R&D experience, we plan to increase our product portfolio by launching new products in Rapid Antigen Vertical, qPCR Diagnostic Kits and NGS.



Geographical Reach:

We plan to sell our products by reaching into new labs post COVID pandemic and by expanding into new markets directly or through distributors / channel partners.



Mergers and Acquisitions:

We are considering exceptional selective mergers and acquisitions in the medium to long term future to get inorganic growth for business. Our ultimate aim is to create maximum value for all our stakeholders.

Manchester Site

We are proud to state the fact that 3B BlackBio had launched its own subsidiary company – TRUPCR[®] Europe Limited in the United Kingdom after entering into a Joint Venture Agreement with its European Distributor, HS Biolabs Limited based in Manchester, UK. This subsidiary was launched with a vision to accelerate the growth of TRUPCR[®] range of molecular diagnostic kits within the European market.

We would like to mention that the UK subsidiary has successfully faced the BSI Audit for getting the ISO 13485:2016 accreditation. With the subsidiary hopefully getting the certification soon, they will start commercial production in UK itself. This will have following benefits:


- 1) the “Made in UK” products will have better acceptability especially in Europe and other regions;
- 2) with products readily available at UK office, the lead time to supply the customer orders will be reduced and the customers will be more confident in “TRUPCR” brand which will eventually lead to increase in revenue.

Although the technical team is in place now, we are working to continuously to increase the sales and marketing team.

In the past few months, the UK subsidiary has participated in 3 International Molecular Diagnostic Conferences. With these conferences, the visibility of TRUPCR Europe has increased and we are getting enquiries for providing distributorships and OEM solutions through which we will expand our footprints across Europe.

With enhanced visibility and full marketing team in place, the real benefits of the subsidiary will start coming in the next financial year.





Utilization of Funds


We have been looking for options to acquire a company in similar business area to get inorganic growth in FY22 and onwards. However, we have not been able to find a suitable company. As due to COVID, most of the lifesciences and molecular diagnostic companies are seeking very high valuations. M&A valuations globally have gone high due to demand from molecular diagnostic companies which are flushed with cash. We will only go for the acquisition if it makes financial sense and meets our internal IRR criteria. We would also be looking at share buyback in FY22/23 post merger, if we are unable to secure a desired acquisition candidate. Our aim is to create maximum value for our shareholders. We will be deploying some funds in the joint venture created in Manchester, UK depending on the need.

Scheme of Amalgamation

The meetings of Equity shareholders and Unsecured Creditors of the company were held on 2nd November, 2022 separately as per the directions issued by the Hon'ble NCLT, Indore bench. The meetings were successfully concluded and voted in favor of amalgamation. The details of the same have been uploaded on the BSE website. We hope the process of amalgamation will be completed soon.

Proposed Listing on National Stock Exchange (NSE)

The most widely accepted objective of the Company is to maximize the value and wealth of its shareholders. Keeping this objective in mind, Company has already initiated the scheme of arrangement/merger to unlock the value of its Material Subsidiary i.e. 3B BlackBio Biotech India Ltd. Post completion of the said scheme of arrangement/merger, company would initiate the listing of its shares on the National Stock Exchange (NSE) also.



Rapid Kit Business Vertical

Our Rapid Kit manufacturing plant is ready for trial runs & we are optimizing the products in R&D which have market potential, other than COVID Testing Kits. We will start with Dengue NS1, Dengue IGM/IGG to cater to the current season and keep on adding products as and when they are ready from the R&D. We will also be launching some novel products in FY 2022-23 which are under R&D Stage.

COVID Rapid Antigen Test is ready and ICMR approved, but demand is very less at present with very low realization.


Company strongly believes that businesses that have an R&D strategy have a greater chance of success than businesses that do not.

Expansion and Additional Capacity

Company is continuously investing in building up additional manufacturing and R&D facilities / capacities to cater to the existing business verticals.

Next-Gen Sequencing (NGS) Vertical

We started working on NGS Kit development in 2019, had developed few parameters, but then COVID came and all activities were suspended. Now we are again reviving the NGS kits revalidations and also development of few more parameters, keeping in mind the global markets. Unfortunately in India due to competition between labs the prices for NGS tests are also very un-remunerative, which was one of the reasons to not aggressively launch kits in India till date. NGS vertical can probably start adding some revenue in later quarters of FY 22-23 only.



R & D




People

- Highly educated team of scientist from varied backgrounds
- Dedicated teams for respective segments
- Separate onco team headed by researchers (Ph.Ds.) from oncology background
- Separate team for infectious parameters headed by researchers (Ph.Ds.) from infectious diseases background

Laboratory Infrastructure

- Separate R&D section
- BSL 2 extraction rooms
- Clean Rooms (ISO-7 / Class 10,000 with double door entry) for assay preparations & downstream activities



Product QC - Our Strength



All TRUPCR® products are passed through stringent QC protocols to ensure optimal performance at customer site

- QC of raw material
- QC of every final lot
- Cherrypicked QC of final batch

Besides above routine QC practices,

Kits are QC checked on respective* real-time cyclers


*We guarantee an unmatched performance of TRUPCR kits on any real-time PCR cyclers, which is the reason that the ordered product is QC checked on the customer's real-time PCR brand and model





3B BlackBio Biotech India Ltd

An ISO 13485:2016 Certified Company



Quality & Regulatory



ISO 13485:2016 & GMP Compliant manufacturing under the Medical Device QMS through BSI



Licensed by CDSCO

Licensed by CDSCO, Govt. Of India; equivalent to FDA, for our top-selling parameters in India



Over 120 Parameters are CE-IVD marked



We currently have USFDA-EUA for our COVID RT-PCR Kit, expanding scope for others.



Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016

This is to certify that:

3B BlackBio Biotech India Limited
a Subsidiary of Kilpest India Limited
7-C, Industrial Area, Govindpura
Bhopal
Madhya Pradesh
462 023
India

Holds Certificate Number: **MD 750282**

and operates a Quality Management System which complies with the requirements of ISO 13485:2016 for the following scope:

Design, development, manufacturing, sales & distribution of PCR, Rapid & ELISA in-vitro diagnostic test kits for use in oncology, genetics, infectious, blood-borne & vector-borne diseases.

For and on behalf of BSI:

Gary E Slack, Senior Vice President - Medical Devices

Original Registration Date: 2022-02-02

Effective Date: 2022-02-02

Latest Revision Date: 2022-02-02

Expiry Date: 2025-02-01



Page: 1 of 1


...making excellence a habit.™


This certificate was issued electronically and remains the property of BSI and is bound by the conditions of contract. An electronic certificate can be authenticated [online](#). Printed copies can be validated at www.bsigroup.com/ClientDirectory

Information and Contact:
BSI Group The Netherlands B.V., John M. Keynesplein 9, 1066 EP Amsterdam, The Netherlands | Tel: +31 20 3460 780
BSI Group The Netherlands B.V. is registered in The Netherlands under number 33264284 | A Member of the BSI Group Holdings B.V.



Technology Focus





Product Segments

Molecular Microbiology

INFECTIONS

Individual Markers

Infectious Panels

Molecular Oncology

CANCERS

Individual Markers

Oncology Panels

Human Genetics

**SYNDROMES &
DISORDERS**


Individual Markers

Genetic Panels



All Inclusive TRUPCR® Products

TRUPCR® range of products offers end-to-end standardized solutions from samples to optimized end-results





Global Recognition

List of recommended BCR-ABL WHO IS tests

Location of Company	Company	Sensitivity	Complete workflow solution available	Includes Reverse Transcriptase step design	Alignment with IS	Simultaneous step for Major and Minor transcript
France, Europe	Elitech - PCR alert kit	MR4.0	X	X	WHO	X
INDIA	3B BlackBio - TRUPCR[®] BCR-ABL1 Kit	MR4.5	✓	✓	WHO	✓
Italy, Europe	AB Analitica Real quality-RS-BCR- ABL p210	MR4.5-5.0	X	X	WHO	X
Netherlands, Europe	QjagenIS MMR kit	MR4.0	✓	X	WHO	X
Netherlands, Europe	Qjagen BCR-ABL1 MbcR RGQ RT-PCR Kit	MR4.5	✓	✓	WHO	X
Singapore	VelaDx Sentosa [®] SA BCR-ABL Major Quantitative RT-PCR Test	MR4.5	✓	✓	WHO	X
USA	Cepheid Gene Xpert	MR4.0	✓	✓	v1 –sample exchange v2- WHO	X
USA	Cepheid Ultra	MR4.5	✓	✓	WHO	X
USA	EntroGen BCR-ABL p210 (MbcR) One-Step Detection Kit	MR5.0	X	✓	WHO	X
USA	Asuragen QuantideX BCR-ABL IS CMR	MR4.7	✓	X	WHO	X
USA	MolecularMD BCR- ABL1IS MR3 Assay TM	MR3.0	X	X	WHO	X

Only INDIAN company listed in global survey*

**Survey conducted by Diaceutics UK, Consultants to Novartis*



Growth Drivers

External Growth Drivers

- Improvement in Indian healthcare industry with high demand in medical tourism
- Increasing number of molecular tests being introduced by labs
- Evolution of disease profiles. New viruses and cancers are being diagnosed
- Increase in evidence-based treatments / Drug response monitoring
- Companion diagnostic assays, which aid in determining prognosis and drug response (pharmacogenomics)

Internal Growth Drivers


- India Specific tests with comprehensive validation on MULTIPLE gene pool
- Unique designing strategy for each test to offer something extra for better actionable information
- Compliance with international standards and guidelines
- Comprehensive coverage of genes/targets
- Positioned with cost advantage
- Faster Turn-around time with unmatched customer support



Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal - 2022




3B BlackBio Biotech India Limited received the Outstanding Achievement Award – 2021 by the Honorable Governor of Madhya Pradesh, His Excellency Shri Mangubhai Patel. The award was conferred to us in recognition of our continuous efforts in the field of R&D for developing various molecular diagnostic assays in the MSME Enterprise category during the 6th Outstanding Achievement Award 2021, held on 10th April, 2022 organized by Federation of Madhya Pradesh Chambers of Commerce and Industry (FMPCCI), Bhopal. This is the second time that we have received this honor, first being the 4th Outstanding Achievement Award 2016 received for Outstanding Achievement in R&D awarded in 2017 by the FMPCCI, Bhopal.



National MSME Award- 2018 by Hon'ble President of India, Shri Ram Nath Kovind.



Hon'ble President of India, Shri Ram Nath Kovind on Friday on the occasion of 20th National Technology Day presented the national award for successful commercialization of indigenous technology at Vigyan Bhavan, New Delhi. 3B BlackBio Biotech India Limited, Bhopal (M.P.) (A subsidiary of Kilpest India Limited) have been declared as the winner of National Award 2018 under MSME category for the successful commercialization of a technology based product- "TRUPCR® BCR ABL1 Quantitative Kit" for detection of BCR-ABL1 fusion gene in patients suffering with chronic myeloid leukemia (CML) & monitor response to drug therapy, on WHO international standards.



Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal - 2017




3B BlackBio Biotech India Limited, Bhopal is awarded with the 'Outstanding Achievement Award in recognition of excellence in R&D through technology in MSME enterprise category', during the 4th Outstanding Achievement Award 2016, held on 12th Aug. 2017 (Saturday), organized by Federation of Madhya Pradesh Chambers of Commerce and Industry (FMPCCI), Bhopal. The award was received by Mr. Dhirendra Dubey (Managing Director), Mr. Nikhil Dubey (Director) & Dr. Akhilesh Rawat (Head R&D), from Hon'ble Chief Minister of M.P. Shri. Shivraj Singh Chouhan



3B BlackBio Biotech India Ltd

An ISO 13485:2016 Certified Company



JAI HIND